Domperid Domperidone Maleate Tablets

1. Indications and Usage
Indigestion Symptoms: Indicated for the relief of dyspeptic symptoms such as abdominal fullness, abdominal pain, belching, excessive intestinal gas, nausea, and vomiting, caused by delayed gastric emptying, gastroesophageal reflux, and esophagitis.
2. Dosage and Administration
Recommended Dose: For adults, the typical dosage is 1 tablet once, 3 times daily.
Timing: Should be taken 15 to 30 minutes before meals or at bedtime.
Duration: Treatment duration should generally not exceed 1 week.
3. Mechanism of Action
D2 Antagonism: Domperidone selectively antagonizes peripheral dopamine D2 receptors.
Prokinetic Effect: It increases gastrointestinal motility and tone, promotes coordinated pyloric contraction, enhances esophageal peristalsis, and inhibits nausea and vomiting.
Blood-Brain Barrier: It has limited ability to cross the blood-brain barrier, resulting in fewer central nervous system adverse reactions compared to other antiemetics.
4. Safety and Warnings
Cardiac Risks: There is a risk of serious ventricular arrhythmias and sudden cardiac death, particularly in patients with heart disease, electrolyte imbalances, or doses exceeding 30 mg/day.
Hyperprolactinemia: May cause elevated serum prolactin levels, leading to galactorrhea, gynecomastia, and menstrual irregularities.
Contraindications: Contraindicated in patients with mechanical gastrointestinal obstruction, gastrointestinal hemorrhage, prolactin-secreting pituitary tumors, known QTc prolongation, moderate to severe hepatic impairment, and known hypersensitivity.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include dry mouth, headache, insomnia, abdominal cramps, and diarrhea.
Clinical Research: Clinical evidence supports its efficacy in accelerating gastric emptying and providing symptomatic relief for functional dyspepsia and acute nausea/vomiting.
6. Drug Interactions
QTc-Prolonging Agents: Concomitant use with strong CYP3A4 inhibitors (e.g., oral ketoconazole, erythromycin, clarithromycin) or other drugs that prolong the QTc interval is contraindicated.
Anticholinergics: May antagonize the prokinetic effects of domperidone.
Acid-Reducing Agents: Antacids or drugs that reduce gastric acidity may decrease the bioavailability of domperidone.
Levodopa: Domperidone can reduce peripheral side effects of levodopa without interfering with its central therapeutic effects.
7. Pharmaceutical Information
Composition: Each tablet contains 10 mg of domperidone (equivalent to 12.72 mg of domperidone maleate).
Excipients: Includes microcrystalline cellulose, starch, povidone, silica, magnesium stearate, and film-coating agents.
Appearance: Pink film-coated tablets.
Storage: Store in a sealed container, protected from moisture.